Trial enrichment for IGF-1R responders using protein or radiologic predictive biomarkers may allow trials to achieve the same statistical significance with fewer patient numbers, and this would theoretically allow more early-phase clinical trials to be conducted, even in rare tumors like ES. Here, IGF1R is linked to Ewing sarcoma.